Scientists are increasingly examining retatrutide, a promising medication from Eli Lilly, as a possible step in weight reduction . Unlike many existing approaches, retatrutide is a dual -action agonist targeting equally GLP-1 and GIP, substances that affect hunger and blood glucose regulation .